GlassScriptPhysician profile
Susan Baldassari
NPI 1245270388
$23,075.99
in general payments reported to CMS, 2019-2025
43 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,479 · 2020: $3,318 · 2021: $4,291 · 2022: $2,683 · 2023: $2,182 · 2024: $1,427 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,293 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.91 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,513.42 | 2019-2025 | Farxiga, Wainua, Airsupra |
| Amgen INC. | $2,400.52 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $2,123.43 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,937.37 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $1,324.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $1,277.39 | 2019-2023 | |
| Abbvie INC. | $1,028.52 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $861.41 | 2024-2025 | Voquezna |
| Pfizer INC. | $797.77 | 2019-2025 | |
| Esperion Therapeutics, INC. | $712.22 | 2021-2023 | Nexletol, Nexlizet |
| E.R. Squibb & Sons, L.L.C. | $699.15 | 2019-2023 | Eliquis |
| Allergan, INC. | $654.66 | 2019-2020 | |
| Lilly USA, LLC | $634.47 | 2019-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $592.81 | 2021 | |
| Amarin Pharma, INC. | $540.80 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Baldassari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.